Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 6/20 | 0.41 |
| ▸ | FPR1 | P21462 | 5/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4558265 | 0.84 | F10 (0.54) | F10CDC7CDK9FPR2FPR1 | |
| SCHEMBL4464011 | 0.76 | FPR2 (0.53) | F10FPR2FPR1 | |
| SCHEMBL4470694 | 0.74 | F10 (0.52) | F10FPR2FPR1 | |
| SCHEMBL6362577 | 0.72 | MAP2K1 (0.39) | F10FPR2FPR1 | |
| SCHEMBL4471526 | 0.72 | F10 (0.47) | F10FPR2 | |
| SCHEMBL4479640 | 0.72 | F10 (0.57) | F10 | |
| SCHEMBL4960540 | 0.70 | NOTUM (0.50) | CDC7CDK9 | |
| SCHEMBL613020 | 0.70 | NOTUM (0.50) | CDC7CDK9 | |
| SCHEMBL30697766 | 0.69 | MAPT (0.48) | FPR2FPR1 | |
| SCHEMBL12285262 | 0.69 | KMT2A (0.47) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524863-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-28 | — | — | US | disclosed |
| US-7157470-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1501798-A4 | SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060247243-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | SMALLHEER JOANNE M | 2006-11-02 | — | — | US | disclosed |
| EP-1501798-A2 | SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004041776-A2 | SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040006062-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247243-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | TFPI, SPINT2, F5 | F10 38/4885CDC7 4376/4885CDK9 1087/4885 |
| US-20040006062-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | TFPI, SPINT2, PRSS1 | F10 31/4885CDC7 4502/4885CDK9 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.